Drugs / HBV-MPL vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00698906 | Jun 1997 → Feb 1998 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00698555 | Mar 1997 → May 1998 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00697229 | Sep 1992 → May 1996 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00696891 | Jun 1997 → May 1999 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBV-MPL vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00698555 ↗ |
| Modality | Vaccine | “HBV-MPL vaccine” NCT00696891 ↗ |
| Route | Intramuscular | “5 different formulations, 2-dose intramuscular injection” NCT00698555 ↗ |